[go: up one dir, main page]

WO2025206186A1 - Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal - Google Patents

Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal

Info

Publication number
WO2025206186A1
WO2025206186A1 PCT/JP2025/012475 JP2025012475W WO2025206186A1 WO 2025206186 A1 WO2025206186 A1 WO 2025206186A1 JP 2025012475 W JP2025012475 W JP 2025012475W WO 2025206186 A1 WO2025206186 A1 WO 2025206186A1
Authority
WO
WIPO (PCT)
Prior art keywords
stress
bifidobacterium adolescentis
reducing
present
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/012475
Other languages
English (en)
Japanese (ja)
Inventor
弘樹 村上
太郎 神
はるか 大内
俊二郎 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Publication of WO2025206186A1 publication Critical patent/WO2025206186A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the present invention relates to a stress-reducing composition, as well as foods, beverages, pharmaceuticals, and feed containing the stress-reducing composition.
  • 1 is a graph comparing the stress-reducing effect of the present invention with the amount of NPF expression in Drosophila.
  • the Bifidobacterium adolescentis SBT2786 strain has been deposited at the National Institute of Technology and Evaluation's National Patent Microorganisms Depositary (NPMD), Biotechnology Center, and is available from that institution.
  • the accession number is shown in Table 1.
  • the Bifidobacterium adolescentis contained in the composition for stress reduction of the present invention can be separated from the obtained culture by a bacteria collection means such as centrifugation and used as it is as the active ingredient of the present invention.
  • the bacterial cells may also be subjected to some kind of treatment. For example, bacterial cells that have been subjected to treatments such as concentration, drying, or freeze-drying may be used, or the bacterial cells may be killed by heat drying or the like, and the treatment method is not particularly limited.
  • Example 2 The following donor bacteria (Example 2, Comparative Examples 2 to 4) were cultured in GAM medium (Nissui Pharmaceutical Co., Ltd.) + 1% glucose (Fujifilm Wako Pure Chemical Industries, Ltd.), and then the bacterial cells were separated by centrifugation. The bacterial cells were washed twice with saline and once with ultrapure water, and then freeze-dried to produce a freeze-dried powder.
  • Example 2 Bifidobacterium strain SBT2786 Comparative Example 2: Bifidobacterium strain SBT0430 (NITEP-03103) Comparative Example 3: Bifidobacterium JCM1275 strain (reference strain) Comparative Example 4: Bifidobacterium NK98 strain (KCCM12297P)
  • Test Procedure Wild-type Drosophila were reared at a temperature of 25° C. under a 12-hour light/dark cycle, and virgin female individuals 5 days after emergence were used for evaluation. (2) The administration sample (lyophilized powder) was mixed with food to a final concentration of 10 mg/mL and administered to Drosophila. As a control, food without bifidobacteria was administered. (3) Three days after administration, the intestines were excised from the Drosophila, and RNA was collected using an RNeasy mini kit (QIAGEN).
  • cDNA was synthesized from the RNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO), and gene expression levels were quantified by real-time PCR using THUNDERBIRD Next SYBR qPCR Mix (TOYOBO). (5) At this time, the primers shown in Table 3 were used. Using rp49 as an endogenous control gene, the expression levels of NPF were compared by the ⁇ Ct method.
  • NPF is the Drosophila homolog of mammalian neuropeptide Y (NPY). NPY has been reported to have anti-stress effects.
  • the NPF expression levels are shown in Table 4 and Figure 1.
  • the NPF expression level was significantly increased compared to the control group.
  • the NPF expression level also increased compared to the control group, but the increase was not as great as in Example 2.
  • the present invention provides a novel composition with stress-reducing properties: a microorganism belonging to the species Bifidobacterium adolescentis, a composition containing said microorganism, and food, beverage, pharmaceutical, and feed containing said composition.
  • stress-reducing properties can be achieved.
  • Bifidobacterium adolescentis SBT2786 strain accession number: NITE BP-03102, date of accession: January 14, 2020
  • depository address 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818, Japan, National Institute of Technology and Evaluation, Biotechnology Center, Patent Microorganism Deposit Center (NPMD).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention aborde le problème de la fourniture : d'une composition de soulagement de stress qui peut soulager le stress, et est excellente en termes de stabilité et de sécurité ; et d'aliments humains et de boissons, de médicaments et d'aliments animaux qui contiennent la composition de soulagement de stress.　L'invention concerne : une composition de soulagement du stress caractérisée en ce qu'elle contient du Bifidobacterium adolescentis en tant que principe actif ; et un aliment humain et une boisson, un médicament de soulagement du stress et un aliment animal de soulagement du stress qui sont caractérisés en ce qu'ils contiennent la composition de soulagement du stress.
PCT/JP2025/012475 2024-03-27 2025-03-27 Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal Pending WO2025206186A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024-052320 2024-03-27
JP2024052320 2024-03-27

Publications (1)

Publication Number Publication Date
WO2025206186A1 true WO2025206186A1 (fr) 2025-10-02

Family

ID=97217272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/012475 Pending WO2025206186A1 (fr) 2024-03-27 2025-03-27 Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal

Country Status (1)

Country Link
WO (1) WO2025206186A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016080449A1 (fr) * 2014-11-19 2016-05-26 株式会社ヤクルト本社 Inhibiteur du stress du réticulum endoplasmique
JP2022071102A (ja) * 2017-09-29 2022-05-13 ユニバーシティ－インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティ 新規な乳酸菌およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016080449A1 (fr) * 2014-11-19 2016-05-26 株式会社ヤクルト本社 Inhibiteur du stress du réticulum endoplasmique
JP2022071102A (ja) * 2017-09-29 2022-05-13 ユニバーシティ－インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティ 新規な乳酸菌およびその用途

Similar Documents

Publication Publication Date Title
JP7273725B2 (ja) 新規ビフィドバクテリウム属細菌及び当該細菌を含む組成物
AU2008222007B2 (en) Agent for reducing visceral fat
DK2478910T3 (en) ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
EP1972208A1 (fr) Composition pour améliorer la flore microbienne intestinale
JP5688376B2 (ja) 経口用のｄｎａ損傷修復促進剤及びエラスターゼ活性抑制剤
JP5891337B2 (ja) ラクトバチルス属菌含有組成物
KR20160130779A (ko) 수면의 질 개선제
EP4410953A1 (fr) Nouveaux probiotiques et utilisation associée
JP7474596B2 (ja) 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
JP2024091698A (ja) 抗ストレス用組成物
JP6894242B2 (ja) 非アルコール性肝障害抑制剤
JP7627369B2 (ja) 糖吸収促進用組成物
JP7606276B2 (ja) 脂質代謝改善用組成物
TWI829090B (zh) 抗憂鬱劑、抗老化劑及抗肥胖劑
Sherwani Probiotics in processed dairy products and their role in gut microbiota health
WO2025206186A1 (fr) Composition pour soulager le stress, aliment humain et boisson, médicament et aliment animal
KR101591978B1 (ko) 항당뇨 및 항고지혈증 활성을 갖는 락토바실러스 브레비스 jb pml-127 균주 및 이의 용도
Shweta et al. In vitro studies on anti-inflammatory, antioxidant and antihyperglycemic activities of potential probiotic Pediococcus acidilactici NCDC 252
WO2022163323A1 (fr) Composition pour améliorer la fonction d'articulation
KR101581826B1 (ko) 항당뇨 및 항고지혈증 활성을 갖는 락토바실러스 브레비스 jb pml-131 균주 및 이의 용도
JP7787936B2 (ja) 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
ÖZDAL OVERVIEW OF PROBIOTICS FROM A BIOTECHNOLOGICAL PERSPECTIVE
JP2025102646A (ja) 肝障害抑制用組成物
JP2025148883A (ja) Ｔｐｈ１遺伝子発現抑制用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25779368

Country of ref document: EP

Kind code of ref document: A1